

S1 Table. Median follow-up period or overall survival, and detailed baseline characteristics of patients in cohort A (diagnosed in 2008-2010) and Cohort B (diagnosed in 2011-2012)

Variables	Cohort A (n=4,063)				Cohort B (n=2,721)				p-value ^{a)}
	Total	Without mortality (n=1,627, 40.0%)	With mortality (n=2,436, 60.0%)	p-value ^{a)}	Total	Without mortality (n=1,427, 52.4%)	With mortality (n=1,294, 47.6%)	p-value ^{a)}	
Median F/U or OS (mo)	33.0 (7.3-50.5)	52.2 (43.8-61.4)	10.5 (3.7-25.8)	-	27.8 (9.7-36.6)	35.2 (29.8-42.0)	8.8 (3.6-19.8)	-	-
Age (yr)	59.0 (51.0-68.0)	58.0 (51.0-65.0)	60.0 (52.0-69.0)	<0.001	60.0 (52.0-69.0)	59.0 (52.0-67.0)	61.0 (52.0-71.0)	< 0.001	< 0.001
Male sex	3,144 (77.4)	1238 (76.1)	1906 (78.2)	0.108	2202 (80.9)	1115 (78.1)	1,087 (84.0)	< 0.001	< 0.001
Body mass index (kg/m ²)	23.7 (21.7-25.8)	23.9 (22.0-26.1)	23.4 (21.4-25.7)	<0.001	23.6 (21.6-25.9)	24.0 (22.0-26.2)	23.2 (21.2-25.5)	< 0.001	0.824
Hypertension	1218 (30.0)	490 (30.1)	728 (29.9)	0.214	887 (32.6)	449 (31.5)	438 (33.8)	0.071	0.027
Diabetes mellitus	937 (23.1)	364 (22.4)	573 (23.5)	0.227	632 (23.2)	308 (21.6)	324 (25.0)	0.007	0.910
Viral etiology	2,962 (72.9)	1,235 (75.9)	1,727 (70.9)	<0.001	1,990 (73.1)	1,096 (76.8)	894 (69.1)	< 0.001	0.326
Hepatitis B	2,468 (60.7)	1,063 (65.3)	1,405 (57.7)	<0.001	1,649 (60.6)	927 (65.0)	722 (55.8)	< 0.001	0.343
Hepatitis C	436 (10.7)	149 (9.2)	287 (11.8)	0.006	306 (11.2)	154 (10.8)	152 (11.7)	0.368	0.663
Hepatitis B+C	58 (1.4)	23 (1.4)	35 (1.4)	0.930	35 (1.3)	15 (1.1)	20 (1.5)	0.238	0.571
Alcohol intake	1,231 (30.3)	428 (26.3)	803 (33.0)	<0.001	842 (30.9)	397 (27.8)	445 (34.4)	< 0.001	0.876
Ascites	889 (21.9)	149 (9.2)	750 (30.8)	<0.001	591 (21.7)	127 (8.9)	464 (35.9)	< 0.001	0.968
Controlled	598 (14.7)	102 (6.3)	496 (20.4)	-	399 (14.7)	98 (6.9)	301 (23.3)	-	-
Uncontrolled	291 (7.2)	37 (2.3)	254 (10.4)	-	192 (7.1)	29 (2.0)	163 (12.6)	-	-
Hepatic encephalopathy	89 (2.2)	14 (0.9)	75 (3.1)	<0.001	57 (2.1)	19 (1.3)	38 (2.9)	0.014	0.675
Mild	75 (1.8)	11 (0.7)	64 (2.6)	-	47 (1.7)	16 (1.1)	31 (2.4)	-	-
Severe	14 (0.3)	3 (0.2)	11 (0.5)	-	10 (0.4)	3 (0.2)	7 (0.5)	-	-
Multiple tumors	1,528 (37.6)	357 (21.9)	1,171 (48.1)	<0.001	1,009 (37.1)	358 (25.1)	651 (50.3)	< 0.001	0.686
Above triple tumors	942 (23.2)	138 (8.5)	804 (33.0)	<0.001	618 (22.7)	139 (9.8)	479 (37.0)	< 0.001	0.668
Maximum tumor diameter (cm)				<0.001				< 0.001	0.858
> 3	2,217 (54.6)	555 (34.1)	1,662 (68.2)	<0.001	1,468 (54.0)	513 (35.9)	955 (73.8)	< 0.001	0.595
> 5	1,459 (35.9)	233 (14.3)	1,226 (50.3)	<0.001	933 (34.3)	200 (14.0)	733 (56.6)	< 0.001	0.164
> 10	798 (19.6)	83 (5.1)	715 (29.4)	<0.001	482 (17.7)	57 (4.0)	425 (32.8)	< 0.001	0.045

Portal vein invasion	905 (22.3)	67 (4.1)	838 (34.4)	<0.001	554 (20.4)	78 (5.5)	476 (36.8)	< 0.001	0.060
Regional LN metastasis	263 (6.5)	18 (1.1)	245 (10.1)	<0.001	167 (6.1)	21 (1.5)	146 (11.3)	< 0.001	0.578
Distant metastasis	350 (8.6)	15 (0.9)	335 (13.8)	<0.001	236 (8.7)	14 (1.0)	222 (17.2)	< 0.001	0.932
Platelet ($\times 10^9/L$)	136 (92-197)	135 (93-187)	137 (92-205)	<0.001	141 (96-194)	132 (94-179)	150 (100-213)	< 0.001	0.430
Serum sodium, mmol/L	139 (137-141)	140 (138-142)	138 (136-141)	<0.001	139 (137-141)	140 (138-142)	138 (136-140)	< 0.001	0.173
ALT (IU/L)	37.0 (24.0-59.0)	34.0 (23.0-52.0)	39.0 (26.0-66.0)	0.001	35.0 (23.0-55.0)	32.0 (22.0-50.0)	39.0 (25.0-62.0)	< 0.001	<0.001
Albumin (g/L)	3.8 (3.3-4.2)	4.0 (3.6-4.3)	3.6 (3.1-4.0)	<0.001	3.9 (3.3-4.2)	4.1 (3.7-4.4)	3.6 (3.1-4.0)	< 0.001	<0.001
Total bilirubin (IU/L)	0.99 (0.70-1.50)	0.80 (0.60-1.20)	1.10 (0.70-1.80)	<0.001	0.90 (0.62-1.40)	0.80 (0.60-1.20)	1.00 (0.70-1.60)	< 0.001	0.001
Serum creatinine (IU/L)	0.90 (0.75-1.00)	0.90 (0.77-1.00)	0.90 (0.72-1.02)	0.008	0.87 (0.72-1.00)	0.86 (0.73-1.00)	0.88 (0.70-1.01)	0.015	0.101
Prothrombin time, INR	1.11 (1.04-1.22)	1.08 (1.02-1.17)	1.13 (1.04-1.25)	<0.001	1.10 (1.03-1.19)	1.07 (1.01-1.16)	1.12 (1.04-1.23)	< 0.001	<0.001
α -Fetoprotein (ng/mL)	41.3 (6.9-625.8)	13.4 (4.7-123.6)	109.6 (12.7-1913.1)	<0.001	29.6 (6.3-483.0)	13.6 (4.7-113.2)	131.2 (10.9-2573.0)	0.005	0.680
Child-Pugh class				<0.001				< 0.001	0.076
A (5-6)	2,991 (73.6)	1,442 (88.6)	1549 (63.6)	-	2,059 (75.7)	1264 (88.6)	795 (61.4)	-	-
B (7-9)	912 (22.4)	166 (10.2)	746 (30.6)	-	569 (20.9)	143 (10.0)	426 (32.9)	-	-
C (10-15)	156 (3.8)	19 (1.2)	137 (5.6)	-	88 (3.2)	19 (1.3)	69 (5.3)	-	-
MELD	9.00 (7.00-11.00)	8.00 (7.00-9.00)	9.00 (8.00-12.00)	<0.001	8.00 (7.00-10.00)	8.00 (7.00-9.00)	9.00 (7.00-11.00)		< 0.001
BCLC stage				<0.001				< 0.001	0.006
Stage 0	342 (8.4)	262 (16.1)	80 (3.3)	-	296 (10.9)	261 (18.3)	35 (2.7)	-	-
Stage A	1,730 (42.6)	1,000 (61.5)	730 (30.0)	-	1,118 (41.1)	774 (54.2)	344 (26.6)	-	-
Stage B	441 (10.9)	137 (8.4)	304 (12.5)	-	319 (11.7)	139 (9.7)	180 (13.9)	-	-
Stage C	1,348 (33.2)	208 (12.8)	1,140 (46.8)	-	870 (32.0)	228 (16.0)	642 (49.6)	-	-
Stage D	202 (5.0)	20 (1.2)	182 (7.5)	-	118 (4.3)	25 (1.8)	93 (7.2)	-	-

Values are presented as median (interquartile range) or number (%). F/U, follow up period; OS, overall survival; LN, lymph node; ALT, aminotransferase; INR, international normalized ratio; MELD, model for end-stage liver disease; BCLC, Barcelona-clinic liver cancer. ^{a)}Student t test, Mann-Whitney test, chi-square test, or Kappa statistics were used for calculating p-values as appropriate.